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Background: Evidence that home telemonitoring for patients with chronic heart failure (CHF) offers clinical benefit
over usual care is controversial as is evidence of a health economic advantage.
Methods: Between January 2010 and June 2013, patients with a confirmed diagnosis of CHF were enrolled and
randomly assigned to 2 study groups comprising usual care with and without an interactive bi-directional remote
monitoring system (Motiva®). The primary endpoint in CardioBBEAT is the Incremental Cost-Effectiveness Ratio
(ICER) established by the groups’ difference in total cost and in the combined clinical endpoint “days alive and not
in hospital nor inpatient care per potential days in study” within the follow-up of 12 months.
Results: A total of 621 predominantly male patients were enrolled, whereof 302 patients were assigned to the
intervention group and 319 to the control group. Ischemic cardiomyopathy was the leading cause of heart failure.
Despite randomization, subjects of the control group were more often in NYHA functional class III–IV, and exhibited
peripheral edema and renal dysfunction more often. Additionally, the control and intervention groups differed in
heart rhythm disorders. No differences existed regarding risk factor profile, comorbidities, echocardiographic
parameters, especially left ventricular and diastolic diameter and ejection fraction, as well as functional test results,
medication and quality of life. While the observed baseline differences may well be a play of chance, they are of
clinical relevance. Therefore, the statistical analysis plan was extended to include adjusted analyses with respect to
the baseline imbalances.
Conclusions: CardioBBEAT provides prospective outcome data on both, clinical and health economic impact of
home telemonitoring in CHF. The study differs by the use of a high evidence level randomized controlled trial (RCT)
design along with actual cost data obtained from health insurance companies. Its results are conducive to informed
political and economic decision-making with regard to home telemonitoring solutions as an option for health care.
Overall, it contributes to developing advanced health economic evaluation instruments to be deployed within the
specific context of the German Health Care System.
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Table 1 Summary of inclusion and exclusion criteria at screening
Inclusion criteria
Confirmed diagnosis of CHF based on ESC guidelines
Symptoms corresponding to NYHA functional class II–IV
AHA classification stages C–D
LVEF ≤ 40 %
Age ≥ 18 years
Patient is discharged after being hospitalized for CHF within the last
12 months
Patient is able to understand the German language
Patient has sufficient eyesight to understand and follow the
instructions communicated by Motiva®
Patient is willing and able to use the required hardware and software
and to maintain a patient diary
Patient is residing within geographical reach of one of the ten
telemonitoring centers in order to receive additional treatment if
required as well as follow-up consultation
Patient gives informed consent regarding benefits and risks related
to the trial, and to sign a participation agreement for the installation
of the home telemonitoring system Motiva®
Exclusion criteria
Myocardial infarction within the past 4 weeks
Heart surgery or any coronary intervention within the past 8 weeks
Cardiogenic shock within the past 4 weeks
Intended cardiac surgery within the next 6 months or priority status
on a waiting list for organ transplantation
Severe chronic and pulmonary illness with an immediate impact on
the main outcome measures
Renal dysfunction requiring dialysis
Dementia or other severe cognitive impairment
Psychiatric disorders prohibiting a participation in the trial
Patient is discharged to or living in an older persons clinic or a
nursing home
Patient is participating in another clinical trial
AHA American Heart Association, staging of heart failure, CHF chronic heart
failure, ESC European Society of Cardiology, LVEF left ventricular ejection
fraction NYHA New York Heart Association, classification of heart failure
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Chronic heart failure (CHF) is one of the most fre-
quently diagnosed diseases causing disability and death
in the Western hemisphere. It is characterized by a
prevalence that increases with age [1]. In Germany, heart
failure is the most common reason for hospitalization
with about 396,000 cases in 2013 [2]. Direct medical
costs related to heart failure account for 1–2 % of total
health care expenditure [3].
In the majority of cases, home telemonitoring solu-
tions in health care delivery to patients with CHF show
advantages over usual care in terms of clinical outcomes.
Several meta-analyses reveal that total mortality and
number of hospitalizations tend to decrease, while pa-
tients’ quality of life improves [4–6]. Two subsequently
published trials (Telemedical Interventional Manage-
ment in Heart Failure trial (TIM-HF) [7], Telemonitor-
ing in patients with Heart Failure trial (TELE-HF) [8])
show neutral findings in general. However, the health
economic impact has not been clearly demonstrated so
far [9]. A meta-analysis by Klersy et al. (2011) states that
the difference in costs between remote patient monitor-
ing and usual care ranges from Euro300 to Euro1000, fa-
voring remote patient monitoring because of a lower
hospitalization rate. Thus, direct costs for hospitalization
were approximated by diagnosis-related group tariffs [10].
A more detailed evaluation of efficiency and economic
feasibility could help to determine cost-effectiveness and
to avoid misallocation of resources [11].
The CardioBBEAT trial was designed to assess the
health economic impact of a dedicated home telemoni-
toring system for patients with CHF based on actual
costs directly obtained from patients’ health care pro-
viders. The present report provides details on the outline
of the study and an analysis of the study population’s
baseline data.
Methods
Study design
CardioBBEAT represents a randomized, controlled, open,
multicenter trial with two prospective study arms. Patients
were recruited at ten study sites from five areas of varying
economic status in Germany: namely, Berlin, Branden-
burg, Bavaria, Hamburg and North Rhine-Westphalia.
This diversity allows for investigating the impact of re-
gional differences in medical care, with general medical
care predominating in rural districts compared to pre-
dominantly specialist care in urban areas. Each site was re-
sponsible for recruiting as well as following-up on their
patients. Specified information about inclusion and exclu-
sion criteria is displayed in Table 1.
The study has been conducted in accordance with the
principles stated in the Declaration of Helsinki, the
Good Clinical Practice (International Conference onHarmonization), and national as well as local regula-
tions. The research protocol was approved by the re-
sponsible ethics committees (Table 2), and written
informed consent was obtained from all patients prior
to any study-related procedures. The study is moni-
tored by an independent external institute to ensure
that every participating site abides by the study proto-
col and to perform external quality control of the data.Setting
During the trial, all patients receive best medical treat-
ment according to the current guidelines of the European
Society of Cardiology (ESC) [12, 13].
Table 2 List of ethical bodies
Ethical body Reference number
Ethik-Kommission für Forschungsfragen der Universität Bayreuth O 1305 – HB/ID
Landesärztekammer Brandenburg, Ethik-Kommission AS 94(a)/2009
Ethikkommission – Ethikausschuss 2 am Campus Virchow-Klinikum Berlin EA2/084/09
Ethik-Kommission für Forschungsfragen der Universität Bayreuth O 1305 – HB/ID
Ethik-Kommission für Forschungsfragen der Universität Bayreuth O 1305 – HB/ID
Medizinische Fakultät der Universität Duisburg-Essen, Ethik-Kommission 10-4536
Ethik-Kommission der Bayerischen Landesärztekammer 7/11014
Universität Würzburg, Ethik-Kommission bei der Medizinischen Fakultät 128/11
Ethik-Kommission der Ärztekammer Hamburg MC-141/11
Ethik-Kommission für Forschungsfragen der Universität Bayreuth O 1305 – GB
Ärztekammer Nordrhein, Ethikkommission 2012451
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treatment as stated above, whereas patients in the inter-
vention group additionally receive home telemonitoring-
supported care that connects them to the participating
care providers by individual guideline-compliant care
plans using the telemedicine-system Motiva® (Philips
Medical Systems GmbH, Hamburg, Germany).
Motiva® is an interactive bi-directional home telemoni-
toring system that provides remote monitoring, em-
powers patients to manage their disease state more
effectively and enables physicians to keep in contact with
the patient at home on a daily basis. Patients measure
their vital signs (blood pressure, heart rate, and weight)
every day and Motiva® transfers the data to the relevant
telemonitoring center. In doing so, signals of decompen-
sation regarding their heart function can be detected at
an early stage and counteractive measures can be taken.
In addition, patients receive information via Motiva®, i.e.
coaching material, evaluations, reminders, and feedback
regarding their health status as well as references to po-
tentially necessary CHF treatment adaptations. If ques-
tionnaires reveal any problems, patients receive a phone
call from the study site. Additionally, patients receive
standardized questionnaires related to symptoms of car-
diac decompensation, hypotension or hypertension or
abnormal pulse rates. A call from the telemedicine cen-
ter is made if patients gain more than 2 kg within 3 days,
if their systolic blood pressure exceeds 140 mmHg or is
lower than 90 mmHg, or their resting heart rate exceeds
80 bpm or is lower than 50 bpm.
A secured broadband connection (Digital Subscriber
Line (DSL) or Universal Mobile Telecommunications
System (UMTS)) and a set-top box turn the patient’s
television into their center of personalized care pro-
tected by a patient-specific password. Thus, patients
can transfer all information about their health status to
their attending physician safely.Motiva® is been provided by Philips Medical Systems
GmbH, Hamburg, Germany. The telecommunication in-
frastructure to transfer patients’ data is made available
by T-Systems International GmbH, Frankfurt, Germany.
Both are provided without any obligations that could in-
fluence the study.Randomization
To assign patients to one of the two study arms,
CardioBBEAT used a centralized stacked randomization
technique. Patients at home who were managed in car-
diologic practices were randomized patient-individually.
Patients primarily managed by their general practitioner
(GP), on the other hand, were cluster-randomized by
their GP’s medical practices, to minimize carry-over
effects and to keep the organizational effort manageable.
The results of the randomization process with regard to
the patients were displayed via the study’s electronic
Case Report Form (eCRF) directly after inclusion into
the trial. The study center in charge did inform the pa-
tients’ attending physicians whether their respective pa-
tients were enrolled in the trial and to which study arm
they were assigned.Treatment patterns
After patients are discharged from inpatient care, their
GPs or outpatient medical specialists will provide their
ambulatory care. These physicians have access to indi-
vidual patient care plans and are authorized to complete
or modify them.
Subjects enrolled in the control group receive best
medical treatment according to the current guidelines of
the European Society of Cardiology (ESC). Subjects en-
rolled in the intervention group are additionally sup-
ported by the telemedicine system Motiva® installed at
the patients’ home usually within 2 weeks.
Table 3 Trial-specific examinations
Enrollment examination
1. Patient briefing
2. Written informed consent
3. Verification of inclusion and exclusion criteria
4. Demography
Sex
Date of birth
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urged to document any health disturbances at least once
a week, such as hospitalizations (date of hospitalization,
reason for admission, and length of stay), consultations
by any physician, and change in medication or dose rate
as well as adverse effects. In addition, every patient has
to participate in 3 trial-specific examinations (Table 3) at
their relevant study site, that take place at the time of
enrollment and after 6 as well as 12 months.Marital status
Size and weight
5. Hemodynamic parameters
Heart rate
Blood pressure (systolic/diastolic)
6. Disease-related parameters
Medical history
CHF (date of diagnosis, aetiology, inpatient treatments, NYHA
classification, AHA stadium)
Comorbidities
Medication
Care plan compilation
6 MWD
7. Health-related quality of life assessment
SF-36v2 (generic quality of life questionnaire)
WHO-5 (generic quality of life questionnaire)
KCCQ (disease-specific quality of life questionnaire)
Follow-up and final examination
1. Demography
Weight
2. Hemodynamic parameters
Heart rate
Blood pressure (systolic/diastolic)
3. Disease-related parameters
CHF (NYHA classification, AHA stadium)
Newly occurring comorbiditiesClinical outcome measures
The primary outcome measure to assess the benefit of
home telemonitoring is the combined clinical endpoint
“days alive and not in hospital nor inpatient care per po-
tential days in study.” For deceased patients, the loss in
lifetime is taken into account by setting the denominator
to 360 days, for patients lost to follow-up, time to last
contact is used. Secondary outcome measures are total
mortality, number of inpatient treatments, length of stay
in hospital or nursing home, functional state of health
and health-related quality of life. These will be deter-
mined by the following parameters: days survived in the
study, number of hospitalizations for any reason during
the study (especially cardiac and heart failure-related
reasons), number of days in hospital or nursing home
per study month, generic (short form health survey
with 36 questions using norm-based scoring (SF-36v2),
World Health Organization Five, well-being index
(WHO-5)) and disease-specific (Kansas City Cardio-
myopathy Questionnaire, (KCCQ)) health-related qual-
ity of life as well as medical condition and capacity of
each patient.
CardioBBEAT may also be able to differentiate between
particular sub-groups (e.g. gender-specific, NYHA-
specific, urban/rural, diabetes mellitus) while analyzing
the effectiveness of the intervention. The expectation
is that several patient groups can be identified which
are particularly suited for home telemonitoring with
regard to clinical and/or economic outcome.Medication
Hospitalizations or admissions to a nursing home
Patient diary monitoring and validation of AE/SAE
6 MWD
4. Health-related quality of life assessment
SF-36v2 (generic quality of life questionnaire)
WHO-5 (generic quality of life questionnaire)
KCCQ (disease-specific quality of life questionnaire)Cost data
CardioBBEAT aims to reflect the impact of home tele-
monitoring within an actual health care setting based
on originally obtained cost data subdivided into cost of
intervention, cost of inpatient and outpatient care, re-
habilitation, nursing, and life-saving appliances. To this
end, cost data are obtained from patients’ health insur-
ance companies and later on validated using the re-
cords of the telemonitoring centers, GPs and medical
specialists as well as patients’ diaries. Health insurance
data will be obtained similarly for both, patients in the
intervention group as well as the control group to avoid
ascertainment bias.
Table 3 Trial-specific examinations (Continued)
In case a patient dies during the trial
Date of death
Cause of death
6 MWD 6-minute walking distance, AE adverse event, AHA American Heart
Association, staging of heart failure, ESC European Society of Cardiology, KCCQ
Kansas City Cardiomyopathy Questionnaire with 23 items for measuring
disease-specific domains in CHF, LVEF left ventricular ejection fraction, NYHA
New York Heart Association, classification of heart failure, SAE serious adverse
event, SF-36v2 short form health survey with 36 questions using norm-based
scoring, WHO-5 World Health Organization Five, well-being index
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methods to determine the economic effectiveness of
home telemonitoring for patients with CHF. Common
approaches for the analysis of cost data such as t tests,
analysis of covariance, bootstrap techniques or permu-
tation tests will be compared regarding their feasibil-
ity, the validity of underlying assumptions and their
stability and robustness in particular if missing values
have to be taken into account.
Especially when analyzing cost data or determining
the Incremental Cost-Effectiveness Ratio (ICER), as-
sumptions are made regarding discount rate, utilities,
projections or estimation of costs, which are based on
uncertain hypotheses. To better understand the out-
comes of these analyses, CardioBBEAT uses sensitivity
analyses considering best-case and worst-case scenarios
to demonstrate in which way the outcomes depend on
these assumptions and how they affect their assessment.Statistical analysis
The primary endpoint ICER, consisting of the group’s
difference in total cost and the combined clinical end-
point “days alive and not in hospital nor inpatient care
per potential days in study”, is calculated with confi-
dence intervals obtained by resampling methods. The
comparative conventional endpoint “event-free survival”
to measure the intervention’s effectiveness is evaluated
using the Kaplan-Meier analysis and log rank tests. To
incorporate possible repeated hospitalizations of a pa-
tient, additional analyses will be performed, e.g. com-
parison of quarterly data and recurrent event analysis.
Secondary outcome measures such as number of stays
in hospital per quarter, health-related quality of life or
time of survival are analyzed via permutation test, co-
variance analysis or log rank test as part of the Kaplan-
Meier analysis.
Furthermore, the trial uses a cluster-randomization
technique and, therefore, correlation effects can evolve
due to the collective treatment of patients in a cardi-
ology center, medical practice, or by a single studynurse. Such effects can result in incorrect p values.
CardioBBEAT uses frailty and multi-level models to as-
sess if and where such correlations occur. The magni-
tude of these correlations will be measured and the p
values will be rectified.
Since at planning stage neither an established statis-
tical method to directly compare costs and ICERs nor
sufficient data to estimate the variability of cost esti-
mates was available, the sample size was determined
based on literature data. With respect to clinical end-
points, the figures were rather stable and converged to a
minimum of 300 patients per group. Since the primary
endpoint was expected to be mainly driven by clinical
events, it was assumed that the sample size will also be
sufficient for the continuously distributed ICER.Results
The study group comprised 621 patients, predominantly
men. Four hundred and seventy-two (76 %) patients
were treated by 449 GPs and 149 (24 %) were treated in
119 cardiologic practices. Three hundred and two pa-
tients were randomized into the intervention group and
319 patients into the control group. Ischemic cardiomy-
opathy was the leading cause of heart failure (59 %). Al-
though randomly assigned, subjects of the control
group were significantly more often in NYHA func-
tional classes III or IV and exhibited peripheral edema
or renal dysfunction, respectively, more frequently
(Table 4). Additionally, the control and intervention
group differed in heart rhythm disturbances (Table 5).
No differences were detected regarding risk factor
profile, comorbidities, echocardiographic parameters,
especially left ventricular and diastolic diameter and
ejection fraction, as well as functional test (6 MWD)
results, medication and quality of life (Tables 4, 5, 6
and 7).
In comparison with recently published German trials
(TIM-HF [7], Interdisciplinary Network for Heart failure
study (INH) [14]) the CardioBBEAT target population
was slightly younger and comprised more male patients
with fewer in NYHA classes III and IV. Nevertheless, all
patients were either categorized in AHA stages C or D
and every fifth patient of the given cohort was diag-
nosed with peripheral edema; this suggests that the
study population had a comparable degree of heart
failure. Regarding comorbidities and risk factor profile,
the study population was very similar, particularly for
diabetes or renal dysfunction. Remarkably, it revealed
a left bundle branch block in approximately 25 % of
the population, a rhythm disorder with a known worse
prognosis [15]. Furthermore, detailed information on
prognostic relevant therapies was documented. Besides
a high proportion of guideline-based pharmacotherapy
Table 4 Baseline characteristics of the CardioBBEAT study participants
Characteristic All patients n = 621 Usual care n = 319 (51 %) Monitoring n = 302 (49 %) p value
Demographic profile
Age (years)
mean ± SD 63.0 ± 11.5 63.5 ± 11.4 62.5 ± 11.6 0.303
median (IQR) 65 (55–72) 65 (55–73) 64 (54–72)
Male sex, n (%) 544 (88) 280 (88) 264 (87) 0.990
Living alone, n (%) 159 (26) 77 (24) 82 (27) 0.442
Education (years) – number of patients (% valid) 607 (98) 311 (98) 296 (98)
mean ± SD 12 ± 3 12 ± 3 12 ± 3 0.803
median (IQR) 11 (10–13) 11 (10–13) 12 (10–13)
Causes of heart failure, n (%) 0.797
Ischemic CM 363 (59) 185 (58) 178 (59)
Non-ischemic CM 258 (42) 134 (42) 124 (41)
NYHA class, n (%) 0.086
II 430 (69) 209 (66) 221 (73)
III 186 (30) 108 (34) 78 (26)
IV 5 (1) 2 (1) 3 (1)
NYHA class III–IV, n (%) 191 (31) 110 (35) 81 (27) 0.048
Peripheral edema, n (%) 131 (21) 83 (26) 48 (16) 0.003
Comorbidities, n (%)
Stroke/TIA 41 (7) 21 (7) 20 (7) 1.000
PAD 56 (9) 24 (8) 32 (11) 0.232
COPD 87 (14) 48 (15) 39 (13) 0.516
Sleep apnea 45 (7) 25 (8) 20 (7) 0.668
Renal dysfunction (GFR ≤ 60 ml/min) 148 (24) 87 (27) 61 (20) 0.048
Depression 51 (8) 24 (8) 27 (9) 0.619
Resuscitation 81 (13) 37 (12) 44 (15) 0.327
Risk factor profile
BMI (kg/m2) – number of patients (% valid) 619 (100) 318 (100) 301 (100)
mean ± SD 28 ± 5 28 ± 5 28 ± 5 0.529
median (IQR) 28 (25–31) 28 (25–32) 27 (25–31)
History of smoking – number/total number (%) 435/620 (70) 221/319 (69) 214/301 (71) 0.684
Diabetes mellitus, n (%) 219 (35) 103 (32) 116 (38) 0.131
Hypertension, n (%) 533 (86) 269 (84) 264 (87) 0.323
BMI body mass index, CM cardiomyopathy, COPD chronic obstructive pulmonary disease, GFR glomerular filtration rate, IQR interquartile range, NYHA New York
Heart Association, classification of heart failure, PAD peripheral arterial disease, TIA transient ischemic attack
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tors, the study population was treated with mineralo-
corticoid receptor blockers in 71 % of all cases. A
cardioverter-defibrillator or a resynchronization system
was implanted in two thirds of our patients (compar-
able to TIM-HF study [7]) with a considerable prognos-
tic impact on primary and secondary endpoints. Table 8
compares the most important baseline characteristics
with TIM-HF [7] and INH [14].Discussion
Several recent randomized controlled trials (RCTs), in-
cluding TIM-HF [7, 16] and INH [14], have proven
the positive clinical effects of home telemonitoring on
several groups of patients diagnosed with CHF. The
meta-analyses of Clark et al. [4], Klersy et al. [5] and
Inglis et al. [6] also showed its potential to improve
several clinical outcomes such as quality of life. How-
ever, many results were not statistically significant
Table 5 Baseline characteristics of the CardioBBEAT study participants - Diagnostic
Characteristic All patients n = 621 Usual care n = 319 (51 %) Monitoring n = 302 (49 %) p value
ECG
Heart rate (1/min) – number of patients (% valid) 616 (99) 315 (99) 301 (100)
mean ± SD 72 ± 14 72 ± 14 72 ± 13 0.862
median (IQR) 71 (63–81) 71 (63–82) 71 (62–80)
Heart rhythm – number/total number (%) 0.031
Sinus rhythm 379/619 (61) 185/318 (58) 194/301 (65)
Atrial fibrillation 78/619 (13) 46/318 (15) 32/301 (11)
Pacemaker ECG 154/619 (25) 86/318 (27) 68/301 (23)
Other 8/619 (1) 1/318 (0) 7/301 (2)
Conduction disorder – number/total number (%)
LBBB 145/543 (27) 69/272 (25) 76/271 (28) 0.543
RBBB 49/544 (9) 28/273 (10) 21/271 (8) 0.383
QRS duration (ms) – number of patients (% valid) 568 (92) 288 (90) 280 (93)
mean ± SD 123 ± 33 125 ± 34 121 ± 32 0.151
median (IQR) 110 (100–144) 116 (100–150) 110 (100–140)
2D echocardiography
LVEDD (mm) – number of patients (% valid) 584 (94) 297 (93) 287 (95)
mean (mm) ± SD 62 ± 9 62 ± 9 63 ± 9 0.580
median (IQR) 62 (57–68) 62 (57–68) 62 (57–68)
LVEF (%) – number of patients (% valid) 619 (100) 317 (100) 302 (100)
mean ± SD 30 ± 7 31 ± 7 30 ± 8 0.580
median (IQR) 31 (25–37) 31 (25–37) 30 (25–36)
Mitral insufficiency – number/total number (%) 0.319
none 102/614 (17) 55/315 (18) 47/299 (16)
mild 370/614 (60) 180/315 (57) 190/299 (64)
moderate 121/614 (20) 70/315 (22) 51/299 (17)
severe 21/614 (3) 10/315 (3) 11/299 (4)
6-minute walk test – number of patients (% valid) 559 (90) 284 (89) 275 (91)
mean (m) ± SD 375 ± 132 376 ± 132 374 ± 131 0.804
median (IQR) 400 (300–458) 404 (300–455) 400 (300–460)
2D two-dimensional, ECG electrocardiogram, IQR interquartile range, LBBB left bundle branch block,LVEDD left ventricular end-diastolic dimension, LVEF left ventricular
ejection fraction, QRS combination of three of the graphical deflections seen on a typical ECG, RBBB right bundle branch block
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despite adequately sized studies.
Another meta-analysis by Klersy et al. [10] focused
on the economic impact of remote patient monitoring.
It showed that management of HF patients by remote
monitoring is cost-saving due to a substantial reduction
in health care resource utilization, mostly driven by a
reduction in the number of HF hospitalizations. How-
ever, cost data in this meta-analysis was estimated using
3 diagnosis-related group reimbursements (minimum,
median, maximum over countries) and 3 different inci-
dence rates and their lower and upper 95 % CI (confi-
dence interval). These facts reflect the requirement foradditional study-derived and reliable evidence based on
originally obtained cost data unlike previously negoti-
ated prices.
In CardioBBEAT, the follow-up care of patients was
more diverse than expected: the number of participating
practices was higher whereas the number of patients per
practice was lower than expected, resulting in an incom-
plete use of the random blocks implemented in the eCRF
and slightly unequal sample sizes between the random
groups. However, slight differences in group sizes are of
no concern with respect to unbiasedness of results.
At first glance, an imbalance in baseline variables
stands out. But, even with perfect randomization the
Table 6 Baseline characteristics of the CardioBBEAT study participants - Therapy
Characteristic All patients n = 621 Usual care n = 319 (51 %) Monitoring n = 302 (49 %) p value
Medication
ACE inhibitor/ARB, n (%) 577 (93) 297 (93) 280 (93) 0.974
Beta blocker – number/total number (%) 591/620 (95) 303/319 (95) 288/301 (96) 0.826
MR antagonist, n (%) 439 (71) 232 (73) 207 (69) 0.291
Diuretics, n (%) 506 (82) 255 (80) 251 (83) 0.360
Glycosides, n (%) 95 (15) 50 (16) 45 (15) 0.876
Amiodarone, n (%) 80 (13) 48 (15) 32 (11) 0.125
Anticoagulation, n (%)
Vitamin K antagonist 231 (37) 122 (38) 109 (36) 0.637
Other 42 (7) 24 (8) 18 (6) 0.538
Devices, n (%)
Pacemaker 101 (16) 61 (19) 40 (13) 0.061
ICD 0.280
with monitoring 63 (10) 31 (10) 32 (11)
without monitoring 242 (39) 134 (42) 108 (36)
CRT-D 89 (14) 40 (13) 49 (16) 0.232
ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, CRT-D cardiac resynchronization therapy combined with defibrillation ICD implantable
cardioverter defibrillator, MR mineralocorticoid receptor
Table 7 Baseline characteristics of the CardioBBEAT study participants – Quality of life
Characteristic All patients n = 621 Usual care n = 319 (51 %) Monitoring n = 302 (49 %) p value
SF-36v2
Physical comp. sum – number of patients (% valid) 581 (94) 299 (94) 282 (93)
mean ± SD 39 ± 10 39 ± 10 38 ± 10 0.458
median (IQR) 38 (32–46) 38 (32–46) 38 (32–45)
Mental comp. sum – number of patients (% valid) 581 (94) 299 (94) 282 (93)
mean ± SD 45 ± 13 45 ± 12 44 ± 13 0.239
median (IQR) 46 (35–56) 46 (36–55) 45 (34–56)
Physical functioning – number of patients (% valid) 591 (95) 304 (95) 287 (95)
mean ± SD 51 ± 27 52 ± 27 50 ± 27 0.445
median (IQR) 50 (30–75) 50 (30–75) 50 (30–70)
WHO-5
Score – number of patients (% valid) 586 (94) 301 (94) 285 (94)
mean ± SD 55 ± 25 55 ± 25 54 ± 25 0.588
median (IQR) 56 (36–76) 56 (36–76) 56 (32–76)
KCCQ
Overall sum – number of patients (% valid) 591 (95) 305 (96) 286 (95)
mean ± SD 59 ± 24 59 ± 24 60 ± 23 0.574
median (IQR) 61 (42–80) 60 (42–80) 62 (42–80)
Clinical sum – number of patients (% valid) 591 (95) 305 (96) 286 (95)
mean ± SD 63 ± 25 63 ± 26 64 ± 24 0.409
median (IQR) 67 (45–85) 67 (44–85) 69 (49–84)
Comp component, IQR interquartile range, KCCQ Kansas City cardiomyopathy questionnaire with 23 items for measuring disease-specific domains in CHF, SF-36v2
short form health survey with 36 questions using norm-based scoring, sum summary, WHO-5 World Health Organization Five, well-being index
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Table 8 Compared baseline characteristics of the CardioBBEAT, TIM-HF and INH study participants
Variable CardioBBEAT TIM-HF INH
Usual care Monitoring Usual care Monitoring Usual care Monitoring
(n = 319) (n = 302) (n = 356) (n = 354) (n = 363) (n = 352)
Demographic profile
Age (years) 63.5 ± 11.4 62.5 ± 11.6 66.9 ± 10.5 66.9 ± 10.8 69.4 ± 11.5 67.7 ± 12.8
Male sex (%) 88 87 82 81 71 71
Living alone (%) 24 27 22 21 35 30
Clinical profile
NYHA class (%)
I 0 0 0 0 2 3
II 65 73 51 50 62 54
III 34 26 49 50 31 40
IV 1 1 0 0 5 3
Risk factor profile
BMI (kg/m2) 28 ± 5 28 ± 5 28 ± 5 28 ± 5 n.a. n.a.
Diabetes mellitus (%) 32 38 39 40 36 36
Hypertension (%) 84 87 66 68 77 72
Diagnostic
Heart rate (1/min) 72 ± 14 72 ± 13 71 ± 13 71 ± 13 80 ± 18 80 ± 20
LVEF (%) 31 ± 7 30 ± 8 27 ± 6 27 ± 6 30 ± 8 30 ± 8
Medication (%)
ACE inhibitor/ARB 93 93 97 94 87 89
Beta blocker 95 96 93 92 79 81
Diuretics 80 83 94 94 86 90
ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, BMI body mass index, LVEF left ventricular ejection fraction, n.a. not available, NYHA
New York Heart Association, classification of heart failure
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between baseline variables is 5 % or 2.45 of the 49 base-
line comparisons in Tables 4, 5, 6 and 7, on average. In
case of independence of the baseline variables, the ob-
served number of significances will thus follow a bino-
mial distribution with p = 0.05. In CardioBBEAT, 4 out
of 49 baseline comparisons (8.2 %) were significant. In
case of independence, 4 or more significant comparisons
would occur in 23 % of the cases even in perfect
randomization. The observed baseline differences could
thus well be a play of chance. However, NYHA func-
tional class, peripheral edema, heart rhythm, and renal
dysfunction were clinically highly relevant variables that
might bias the conclusions even if evoked by chance.
Therefore, the statistical analysis plan was extended to
include adjusted analyses with respect to the baseline
imbalances.
Conclusions
CardioBBEAT is a RCT that adds a comprehensive cost
assessment to the clinical component of the studyincluding actual costs generated by patients, health
services and health products. The corresponding data
have been obtained directly from patients’ health insur-
ances including statutory sickness funds and private in-
surances. This will provide more reliable information
about the cost-effectiveness of home telemonitoring in
CHF patients based on the actual health care setting.
CardioBBEAT may also be able to differentiate between
particular sub-groups (gender-specific, NYHA-specific,
urban/rural, diabetes mellitus) while analyzing the ef-
fectiveness of the intervention. The expectation is that
important patient groups, which are better suited for
the input of telemedicine with regard to the clinical
and/or economic outcome, can be identified. The study
results, reflecting a guideline-compliant, highly accurate
treatment of the whole CardioBBEAT study population
shown above, will significantly contribute to the exist-
ing data basis on home telemonitoring in CHF. There-
fore, it adds to informed political and economic
decision-making within the specific context of the
German Health Care System.
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